<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04203927</url>
  </required_header>
  <id_info>
    <org_study_id>21403</org_study_id>
    <secondary_id>1R01HL142250-01A1</secondary_id>
    <nct_id>NCT04203927</nct_id>
  </id_info>
  <brief_title>Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes</brief_title>
  <acronym>EJB051</acronym>
  <official_title>Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to test in T2DM patients, whether, compared to placebo, 12 weeks of SGLT-2
      inhibitor improves post-absorptive, post-insulin infusion or postprandial insulin action to
      enhance Cardiac Muscle vascular function and whether changes correlate with improved GV or
      postprandial hyperglycemia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will study 32 T2DM subjects measuring cardiac muscle vascular function
      before and after a 4 hour insulin clamp ( protocol A) and before and after a mixed meal
      (protocol B). Then subjects will be randomized into 2 groups: Group 1 will undergo a 12 week
      intervention of Empagliflozin, and Group 2 will do 12 weeks of Placebo. The intervention will
      be single blinded. At the end of the 12 week intervention subjects will repeat protocol A and
      B.

      The study's primary objective is to assess whether, compared to placebo, 12 weeks of
      Empagliflozin improves post-absorptive or postprandial insulin action to enhance myocardial
      perfusion (MP) and whether changes of MP correlate with improved glucose variability or
      postprandial hyperglycemia
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 22, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>subjects will not know whether the study drug they are taking is Empagliflozin or Placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial microvascular perfusion</measure>
    <time_frame>Between baseline and 12 weeks treatment</time_frame>
    <description>Vascular measure of myocardial perfusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Flow Mediated Dilation (FMD) Vascular measure of conduit artery stiffness Change in Flow Mediated Dilation (FMD) between baseline and after 2 hour insulin clamp Vascular measure of conduit artery stiffness Flow Mediated Dilation ( FMD)</measure>
    <time_frame>Between baseline and 12 weeks of treatment.</time_frame>
    <description>Vascular measure of conduit artery stiffness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Augmentation Index ( AI)</measure>
    <time_frame>Between baseline and 12 weeks of treatment.</time_frame>
    <description>Measurement of central artery stiffness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse Wave Velocity ( PWV)</measure>
    <time_frame>Between baseline and 12 weeks of treatment</time_frame>
    <description>Measurement of central artery stiffness</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Type2 Diabetes</condition>
  <condition>Insulin Sensitivity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SGLT-2 inhibitor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 25 MG</intervention_name>
    <description>SGLT-2 inhibitor</description>
    <arm_group_label>Empagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A1C &gt; 6.5 and &lt;9%

          -  Never on SGLT-2i (eg: Jardiance, Invokana, Farxiga, Steglatro)

          -  On stable dose of oral hypoglycemic agents &gt;3 months

          -  On stable dose of other medications for &gt;3 months

          -  BMI-&lt;35

        Exclusion Criteria:

          -  • Smoking presently or in the past 6 months

               -  Taking insulin

               -  BP &gt;160/90

               -  BMI &gt;35

               -  History of congestive heart failure, ischemic heart disease, severe pulmonary
                  disease, liver or kidney disease.

               -  Any vascular disease such as myocardial infarction, stroke, peripheral vascular
                  disease

               -  History of cancer or psychiatric disease

               -  Presence of an intracardiac or intrapulmonary shunt (we will screen for this by
                  auscultation during the physical exam by PI).

               -  Pregnant or breastfeeding.

               -  Known hypersensitivity to perflutren (contained in Definity)

               -  Screening O2 saturation &lt;90%

               -  History of recurrent UTI/bladder/kidney infections—eGFR is below 45 mL/min/1.73.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugene J Barrett, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eugene J Barrett, MD PhD</last_name>
    <phone>434-924-1263</phone>
    <email>ejb8x@virginia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lee Hartline, MEd</last_name>
    <phone>434-924-5247</phone>
    <email>lmh9d@virginia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugene Barrett, MD, PhD</last_name>
      <phone>434-924-1175</phone>
      <email>ejb8x@virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Zhenqi Liu, MD</last_name>
      <email>zl3e@virginia.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Nishimura R, Tanaka Y, Koiwai K, Inoue K, Hach T, Salsali A, Lund SS, Broedl UC. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study. Cardiovasc Diabetol. 2015 Jan 30;14:11. doi: 10.1186/s12933-014-0169-9.</citation>
    <PMID>25633683</PMID>
  </reference>
  <reference>
    <citation>Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohneberg K, Johansen OE, George JT, Hantel S, Bluhmki E, Lachin JM. How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care. 2018 Feb;41(2):356-363. doi: 10.2337/dc17-1096. Epub 2017 Dec 4.</citation>
    <PMID>29203583</PMID>
  </reference>
  <reference>
    <citation>Zhao L, Chai W, Fu Z, Dong Z, Aylor KW, Barrett EJ, Cao W, Liu Z. Globular adiponectin enhances muscle insulin action via microvascular recruitment and increased insulin delivery. Circ Res. 2013 Apr 26;112(9):1263-71. doi: 10.1161/CIRCRESAHA.111.300388. Epub 2013 Mar 4.</citation>
    <PMID>23459195</PMID>
  </reference>
  <reference>
    <citation>Liu J, Jahn LA, Fowler DE, Barrett EJ, Cao W, Liu Z. Free fatty acids induce insulin resistance in both cardiac and skeletal muscle microvasculature in humans. J Clin Endocrinol Metab. 2011 Feb;96(2):438-46. doi: 10.1210/jc.2010-1174. Epub 2010 Nov 3.</citation>
    <PMID>21047922</PMID>
  </reference>
  <reference>
    <citation>Scognamiglio R, Negut C, De Kreutzenberg SV, Tiengo A, Avogaro A. Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients. Circulation. 2005 Jul 12;112(2):179-84. Epub 2005 Jul 5.</citation>
    <PMID>15998667</PMID>
  </reference>
  <reference>
    <citation>Chai W, Liu J, Jahn LA, Fowler DE, Barrett EJ, Liu Z. Salsalate attenuates free fatty acid-induced microvascular and metabolic insulin resistance in humans. Diabetes Care. 2011 Jul;34(7):1634-8. doi: 10.2337/dc10-2345. Epub 2011 May 26.</citation>
    <PMID>21617098</PMID>
  </reference>
  <reference>
    <citation>Kovatchev BP, Clarke WL, Breton M, Brayman K, McCall A. Quantifying temporal glucose variability in diabetes via continuous glucose monitoring: mathematical methods and clinical application. Diabetes Technol Ther. 2005 Dec;7(6):849-62.</citation>
    <PMID>16386091</PMID>
  </reference>
  <reference>
    <citation>Kovatchev BP. Metrics for glycaemic control - from HbA(1c) to continuous glucose monitoring. Nat Rev Endocrinol. 2017 Jul;13(7):425-436. doi: 10.1038/nrendo.2017.3. Epub 2017 Mar 17. Review.</citation>
    <PMID>28304392</PMID>
  </reference>
  <reference>
    <citation>Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2016 Mar 17;374(11):1094. doi: 10.1056/NEJMc1600827.</citation>
    <PMID>26981940</PMID>
  </reference>
  <reference>
    <citation>Neal B, Perkovic V, Matthews DR. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Nov 23;377(21):2099. doi: 10.1056/NEJMc1712572.</citation>
    <PMID>29166232</PMID>
  </reference>
  <reference>
    <citation>Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14.</citation>
    <PMID>27299675</PMID>
  </reference>
  <reference>
    <citation>Kolka CM, Rattigan S, Richards SM, Barrett EJ, Clark MG. Endothelial Na+-D-glucose cotransporter: no role in insulin-mediated glucose uptake. Horm Metab Res. 2005 Nov;37(11):657-61.</citation>
    <PMID>16308832</PMID>
  </reference>
  <reference>
    <citation>Chai W, Wang W, Liu J, Barrett EJ, Carey RM, Cao W, Liu Z. Angiotensin II type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use. Hypertension. 2010 Feb;55(2):523-30. doi: 10.1161/HYPERTENSIONAHA.109.145409. Epub 2009 Dec 7.</citation>
    <PMID>19996061</PMID>
  </reference>
  <reference>
    <citation>Wang N, Ko SH, Chai W, Li G, Barrett EJ, Tao L, Cao W, Liu Z. Resveratrol recruits rat muscle microvasculature via a nitric oxide-dependent mechanism that is blocked by TNFα. Am J Physiol Endocrinol Metab. 2011 Jan;300(1):E195-201. doi: 10.1152/ajpendo.00414.2010. Epub 2010 Oct 26.</citation>
    <PMID>20978231</PMID>
  </reference>
  <reference>
    <citation>Fu Z, Zhao L, Aylor KW, Carey RM, Barrett EJ, Liu Z. Angiotensin-(1-7) recruits muscle microvasculature and enhances insulin's metabolic action via mas receptor. Hypertension. 2014 Jun;63(6):1219-27. doi: 10.1161/HYPERTENSIONAHA.113.03025. Epub 2014 Apr 7.</citation>
    <PMID>24711523</PMID>
  </reference>
  <reference>
    <citation>Nalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab. 2010 Apr;12(4):288-98. doi: 10.1111/j.1463-1326.2009.01160.x. Review.</citation>
    <PMID>20380649</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 17, 2019</study_first_submitted>
  <study_first_submitted_qc>December 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2019</study_first_posted>
  <last_update_submitted>February 21, 2020</last_update_submitted>
  <last_update_submitted_qc>February 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Eugene Barrett</investigator_full_name>
    <investigator_title>Prinicipal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

